Follistatin-315: Mechanism, Dosing & Research Data

Follistatin-315 is the shorter splice isoform of follistatin lacking the heparin-binding C-terminal extension present in follistatin-344. This structural difference dramatically alters its biodistribution: FST315 circulates freely in plasma and distributes systemically, while FST344 is anchored to cell-surface heparan sulfate proteoglycans. FST315 is the predominant circulating isoform and the therapeutically relevant form for systemic activin and myostatin neutralization.

Mechanism of Action

Binds activin A (Kd ~0.05 nM) and myostatin with 2:1 stoichiometry (two FST molecules per activin dimer), completely blocking type I/II receptor access
Circulates freely in plasma without HSPG anchoring; reaches systemic targets including muscle, bone, and gonads at physiological concentrations
FST344 is locally active at cell surfaces; FST315 provides the systemic neutralization buffer for circulating activin/myostatin
In muscle: FST315 neutralizes myostatin and activin A/B, reducing SMAD2/3 signaling in myofibers, promoting hypertrophy and reducing atrophy
In gonads: FST315 regulates FSH by neutralizing activin B in the pituitary-gonadal axis; FST315 rise during folliculogenesis reduces FSH to prevent over-recruitment

Research Findings

FST315 knockout models show higher circulating activin levels and impaired muscle mass maintenance vs FST344 knockouts, confirming FST315 as the systemic regulator
Recombinant FST315 increased muscle mass more than FST344 in myostatin-inhibition protocols due to better systemic distribution
AAV-FST315 gene therapy: single intramuscular injection produced 3-4-fold muscle mass increase in mice maintained for over 12 months (compared to ~2-fold for AAV-FST344)
FST315/FST344 ratio shifts with reproductive cycle; FST315 dominates when systemic activin control is needed (corpus luteum stage)
Spinal muscular atrophy (SMA) and Duchenne muscular dystrophy models: FST315 delivered via AAV improved muscle function and survival significantly

Research Protocols

Muscle hypertrophy: recombinant FST315 at 1-5 mg/kg SC or IV 3x/week in mdx or wild-type mice; measure muscle mass and grip strength at 8 weeks
AAV-FST315 gene therapy: 10^11-10^12 vg/mouse IM injection; sustained follistatin expression and muscle mass tracked for months
In vitro differentiation: 10-100 ng/mL FST315 during myoblast differentiation; compare myotube diameter vs FST344
Activin neutralization assay: FST315 pre-incubation with activin A at molar ratios 2:1 to 10:1; residual SMAD2 phosphorylation in reporter cells

Interactions

Follistatin-344: complementary isoform; FST344 handles local (cell surface) neutralization while FST315 handles systemic regulation
Myostatin and activin A: primary neutralization targets; FST315 reduces their circulating bioavailability
FSH: FST315 reduces activin-driven FSH from pituitary; FST315 rise in late follicular phase is part of the ovarian cycle regulation

Safety Profile

Recombinant FST315 well tolerated in animal studies at anti-myostatin doses. AAV-FST315 gene therapy in NHP showed muscle enlargement without systemic organ effects at tested doses. Concern: long-term systemic activin suppression may affect reproductive axis and bone. Not clinically approved.